Stockholm June 1, 2023

Neobiomics and Bios Therapeutics have entered into a Distribution Agreement under which Bios Therapeutics has the exclusive rights to register, market and sell Neobiomics’ proprietary product ProPrems® in Greece.

ProPrems® is a high-quality product for safe food supplementation with one billion bacteria of three well-documented strains – Bifidobacterium infantis, Bifidobacterium lactis and Streptococcus thermophilus.

Dr. Stefan Johansson, CEO and co-founder of Neobiomics AB, says: “We are very happy to extend our distributor network into Greece. With its niche network, Bios Therapeutics is the perfect partner for us, with capacity to make ProPrems® readily available in Greece.”

Michalis Siachos, CEO and founder of Bios Therapeutics, comments: “We are delighted to work with Neobiomics, an innovative company with an R&D pipeline of products within neonatal intensive care. This partnership represents a significant addition to our portfolio in Greece and fits with our strategy to build a strong and niched business.”

About Neobiomics
Neobiomics AB was founded in 2016 by Stefan Johansson and Philipp Novak to solve unmet needs in pediatric health care, affiliated to the Accelerator Pilot Program of the Karolinska Institutet Innovation AB. The first product ProPrems® is used in many hospitals in Europe.